- Conditions
- Sickle Cell Disease
- Interventions
- tAN device
- Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 770
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Sickle Cell Disease
- Interventions
- Hematopoietic Stem Cell Transplantation
- Biological
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 3 Years to 19 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 16 more
- Conditions
- Sickle Cell Disease
- Interventions
- Exercise Test (CIIT)
- Other
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Memphis, Tennessee
- Conditions
- Sickle Cell Disease
- Interventions
- Motixafortide
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Bethesda, Maryland • Memphis, Tennessee
- Conditions
- Bone Marrow Transplantation, Sickle Cell Disease
- Interventions
- fludarabine
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • St. Petersburg, Florida + 7 more
- Conditions
- Sickle Cell Disease
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 15 Years to 44 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Memphis, Tennessee
- Conditions
- Hematologic Diseases, Anemia, Sickle Cell
- Interventions
- Intravenous Ketorolac, Ibuprofen
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Alemtuzumab, low dose total body irradiation, Sirolimus
- Drug
- Lead sponsor
- Robert Nickel
- Other
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 5
- States / cities
- Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
- Conditions
- Sickle Cell Anemia
- Interventions
- Ambrisentan, Placebo
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Sickle Cell Disease, Diffuse Myocardial Fibrosis
- Interventions
- Losartan
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 6 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Anemia, Sickle Cell
- Interventions
- HBI-002
- Drug
- Lead sponsor
- Hillhurst Biopharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Sickle Cell Disease
- Interventions
- Osivelotor
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 6
- States / cities
- Baton Rouge, Louisiana • New Orleans, Louisiana • Madison, Mississippi + 2 more
- Conditions
- Sickle Cell Disease, Genetic Disease, Hematologic Diseases, Anemia, Sickle Cell
- Interventions
- Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)
- Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 279 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Oakland, California • Augusta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Anemia, Sickle Cell
- Interventions
- GBT440
- Drug
- Lead sponsor
- Global Blood Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Sickle Cell Disease, Sickle Cell Nephropathy
- Interventions
- Atorvastatin, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Sickle Cell Anemia
- Interventions
- ACZ885, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 8 Years to 20 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Augusta, Georgia • Greenville, North Carolina
- Conditions
- Race-related Stress, Depression, Anxiety, Quality of Life, Stress Reaction
- Interventions
- ACT for SCD
- Behavioral
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 14 Years to 21 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Beta-Thalassemia, Transfusion Dependent Beta-Thalassaemia
- Interventions
- autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452
- Biological · Device
- Lead sponsor
- Daniel Bauer
- Other
- Eligibility
- 13 Years to 40 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Disease
- Interventions
- IMR-687, Placebo
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 11 more
- Conditions
- Sickle Cell Disease
- Interventions
- bb1111
- Genetic
- Lead sponsor
- Genetix Biotherapeutics Inc.
- Industry
- Eligibility
- 2 Years to 50 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
- Conditions
- Sickle Cell Disease
- Interventions
- Etavopivat, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 49
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
- Conditions
- Sickle Cell Disease (SCD)
- Interventions
- Not listed
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 3 Years to 20 Years
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Wilmington, Delaware • Washington D.C., District of Columbia + 19 more
- Conditions
- Sickle Cell Disease
- Interventions
- TAK-755, Placebo
- Drug · Other
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more
- Conditions
- Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
- Interventions
- Hemanext ONE System, Conventional RBCs
- Device
- Lead sponsor
- Hemanext
- Industry
- Eligibility
- 7 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 5
- States / cities
- Farmington, Connecticut • Atlanta, Georgia • Chicago, Illinois + 2 more